Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Unknown 39Recruiting 25Completed 23Not yet recruiting 10Active not recruiting 3Withdrawn 2Terminated 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Stomach Neoplasms 1Rectal Neoplasms 1Colonic Neoplasms 1Adenocarcinoma 1

Interventions

Cyclophosphamide 390Carboplatin 344Gemcitabine 332pembrolizumab 329Cisplatin 328Paclitaxel 297Radiotherapy 296Docetaxel 286Bevacizumab 253Rituximab 234Capecitabine 223Nivolumab 220Dexamethasone 206Fluorouracil 190fludarabine 177Oxaliplatin 177Pemetrexed 153Doxorubicin 153Irinotecan 148Leucovorin 144Etoposide 144Cytarabine 133Cetuximab 129Bortezomib 129fludarabine phosphate 128Lenalidomide 126Erlotinib Hydrochloride 120Filgrastim 119Temozolomide 113Radiosurgery 113

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × XELOX × Clear all
NCT00127036 2017-03-23

Trial for Microarray Analysis of Colon Cancer Outcome-A (MACCO-A)

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Terminated
65 enrolled 8 charts
Gastrointestinal

Adenocarcinoma, Colonic Neoplasms, Rectal Neoplasms

NCT01748851 2014-11-04

XELOX Versus FOLFOX for Advanced Gastric Cancer (AGC)

Dong-A University Hospital

Phase 3 Terminated
42 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡